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Over the last decade, it has become apparent that the complex interactions between components of the
mucosal microflora and the mucosal immune system can involve either direct contact with dendritic cells
in the lamina propria or, alternatively, contact with epithelial cells lining the mucosa that then influence the
function of dendritic cells. Although in some cases these interactions involve signaling specific to particular
organisms and in others, to classes of organisms, a common theme is that signaling is invariably channeled
through receptors that address many organisms or all organisms such as the pattern-recognition receptors
TLR andNLR. Here, I review this informationwith the intention of identifying how themucosal microflora influ-
ences specific functions of the mucosal immune system such the production of particular cytokines as well
as broader functions such as the maintenance of mucosal immune homeostasis and host defense.Introduction
In this review, I will consider some of the main mechanisms by
which bacteria in the gastrointestinal tract (hereafter called the
microflora) communicate with and influence mucosal cytokine
responses through their direct or indirect interactions with
mucosal dendritc cells (DCs). As a preamble to this discussion
it is useful to briefly review current knowledge concerning the
major DC subsets residing in the intestinal lamina propria, i.e.,
the DCs that are interacting with the microflora in the various
studies discussed below.
In the last several years, lamina propria DCswere grouped into
two major subsets, CD11b+ DCs and CD103+ DCs. The former
could be broadly defined as DCs that induce effector T cells
and are involved in the induction of T helper 1 (Th1) and Th17
T cells (Denning et al.,2007; Uematsu et al.,2008) in ATP-induced
responses (Atarashi et al., 2008) and in TLR5-induced responses
(Uematsu et al., 2008). The latter could be described as cells
that induce Treg cells and that imprint T cells with gut-homing
markers such as a4b7 and CCR9 (Coombes and Powrie,
2008). However, more recently, a new classification of DCs has
been emerging—one based mainly on the origin of the DC
subsets (Varol et al., 2009; Bogunovic et al., 2009). One subset
consist of cells that are CD103+CX3CR1
, which arise from
DC-committed precursors (pre-DCs) and common monocyte
and dendritic cell precursors under the influence of Flt3 ligand.
A second DC subset consists of cells that are CD11b+CD14+
CX3CR1
+ that are derived from Ly6lo monocytes driven by
GM-CSF. Thus, the older classification based on CD11b and
CD103 is giving way to a classification based on these markers
plus the presence or absence of CX3CR1.
With respect to the function of the DCs in the newly defined
categories of cells, the CX3CR1
+ subset tend to express higher
amounts of costimulatory molecules such as CD70, CD80, and
CD86 and contain the cells capable of forming antigen-sampling
dendrites (see discussion below) (Varol et al., 2009, this issue of
Immunity). In addition, these DCs produce higher amounts of the
cytokine TNF-a as compared to the CX3CR1
 DCs. Thus, these
DCs are the effector T cell-inducing cells. In contrast, theCX3CR1
 DC subset contains the cells that respond to oral anti-
gens (or luminal bacteria) and that then migrate to local draining
nodes where they present these antigens to T cells (Coombes
et al., 2007; Jaensson et al., 2008). Their expression of CD103,
a ligand of E-cadherin expressed by epithelial cells, may facili-
tate close association with epithelial cells as well as exposure
to differentiation factors derived from the latter (see discussion
below). This, plus the fact mentioned above that these DCs
induce Treg cells, suggest that these are the DCs that maintain
gut homeostasis.
Antigen Sampling by Mucosal Dendritic Cells
A single layer of epithelial cells separates the gut microflora from
the main elements of the mucosal immune system and yet
provides a remarkably efficient barrier to entry of the microflora
into the lamina propria proper (Groschwitz and Hogan, 2009). It
would be incorrect, however, to consider this barrier imperme-
able even when inflammation is not present. On the contrary,
there are several mechanisms by which DCs in the mucosa
continuously sample the gut microflora and thereby create
a mucosal cell population that is in balance with the mucosal
antigenic milieu. Perhaps the best known is antigen uptake by
the M cells that are present on the surface of the follicular tissue
and that transfer antigenic material to DCs just beneath the
epithelial layer of the Peyer’s patches and other follicular tissue
(Corr et al., 2008). The far-more-numerous columnar epithelial
cells can also take up antigen, albeit much less efficiently than
M cells (Kyd and Cripps, 2008). This somewhat poorly described
transport process facilitates DC exposure (and perhaps T cell
exposure) to antigen in the many areas of the mucosa where
M cells do not exist (McCole and Barrett, 2007). Another uptake
mechanism only recently established is one that is mediated by
the fetal Fc receptor, or FcRn, a Fc receptor once considered to
be expressed only in fetal or neonatal tissues but now known to
be expressed in adult animals as well (Baker et al.,2009). This
receptor binds IgG by a pH-sensitive mechanism that facilitates
vesicular bidirectional transport of intact IgG or IgG-antigen
complexes across mucosal epithelial cells. By this means, theImmunity 31, September 18, 2009 ª2009 Elsevier Inc. 377
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associated with lumenal bacteria) and deliver them to underlying
DCs to initiate T cell responses; alternatively, it can deliver IgG
antibodies to the mucosal lumen for the purpose of host defense
against epithelial cell-associated pathogens (Yoshida et al.,
2004; Yoshida et al. 2006). Finally, it has recently been shown
DCs that acquire lumenal antigen (such as flagellin) by thismech-
anism can initiate antibody responses that aggravate ongoing
inflammation; thus, the FcRn may play a role in mucosal inflam-
matory disorders (Kobayashi et al., 2009). Together, these
studies establish the FcRn IgG transepithelial transport system
as a potentially important mechanism of DC antigen sampling;
however, further studies are needed to address the quantitative
importance of this mechanism.
A fourth mechanism of sampling and the one that has received
the most recent attention is sampling by DCs themselves. Thus,
as shown initially by Rescigno et al., crosstalk between organ-
isms in the mucosal lumen of the gut and the mucosal immune
system can occur via antigen-sampling DCs that extend
processes (sampling dendrites) through the epithelium without
disruption of tight junctions (Rescigno et al., 2001). In work
utilizing two-photon microscopy, these processes appear to
form apical ‘‘balloons’’ upon reaching the gut lumen (Chieppa
et al., 2006). Assuming that such structures are not artifacts of
imaging, they could function to increase the area of contact
with lumenal organisms. The mechanism or mechanisms by
which the sampling dendrites actually interact with organisms
is unknown. In one study, the sampling dendrites were found
only in the terminal ileum of the undisturbed gut, consistent
with the presence of higher amounts of organisms at this location
and the fact that mice subjected to oral antibiotic treatment
manifest reduced numbers of sampling dendrites (Niess et al.,
2005). However, in another study such dendrites were more
prevalent in the proximal than in the distal undisturbed gut and
were increased in the latter area only upon introduction of inva-
sive or noninvasive Salmonella organisms (Chieppa et al., 2006).
The induction of DC-sampling dendrites by organisms is
greatly diminished in mice with epithelial cells lacking the
adaptor molecule MyD88, indicating that Toll-like receptor
(TLR) signaling of epithelial cells drives the formation of these
dendrites (Chieppa et al., 2006). Work by Niess et al. indicated
that such signaling might involve secretion of CX3CL1 (fractal-
kine) because extensions were not found in mice not expressing
CX3CR1; furthermore, such mice exhibited impaired bacterial
uptake and more susceptibility to Salmonella infection (Niess
et al., 2005). However, this view was opposed by Chieppa
et al. who provided evidence that CX3CR1
 cells could also
form sampling dendrites and that, in fact, CX3CL1 was not
involved either in baseline expression of such dendrites or in their
induction by Salmonella (Chieppa et al., 2006). Finally, in the
Chieppa et al. studies, CCL20 expression was increased in areas
where sampling dendrites were induced and it was suggested
that this chemokinemay also play some inductive role. However,
DC numbers are not increased at these sites and thus this or
other chemokines don’t act in this setting as chemoattractants
but rather as agents that affect the dendrite-forming capability
of the DCs.
The fact that antigen-sampling DCs are involved in host
defense against Salmonella infection as indicated above378 Immunity 31, September 18, 2009 ª2009 Elsevier Inc.suggests that these cells are involved in effector cell rather
than regulatory cell responses. Recent work supports this
conclusion in that it shows CD103 is not present on CX3CR1
+
antigen-sampling cells and vice versa (Niess, 2009). In addition,
only CD103+ cells induce Foxp3+ Treg cells and only CX3CL1
+
cells induce IL-17 and IFN-g. This interesting finding, if corrobo-
rated, indicates that a strong division of labor among DCs exists
in the mucosal immune system (see Figure 1).
Effect of Specific Members of the Gut Microflora
on Mucosal Cytokine Production
Several important studies have shown that specific organisms
(or relatively circumscribed subpopulations of organisms) have
defined effects on mucosal immune function. The significance
of these studies lies in the fact that they point to possible
methods of modifying mucosal responses via the introduction
of specific organisms or, better, components of specific organ-
isms. The first such study to be discussed focused on organisms
in the small intestine that induce CD4+ IL-17-producing cells
under steady state (noninflammatory) conditions (Ivanov et al.,
2008). This study wasmotivated by the observation that whereas
10%–15% of CD4+ T cells in the small intestine express IL-17,
only 2% of this cell population express IL-17 in the large
intestine. Thus, the small intestine is an unexpectedly fertile
area of IL-17 development, as first reported by Becker and his
colleagues (Becker et al., 2003). In seeking to understand why
this was so, Ivanov et al. noted that IL-17 cells do not appear
in the small intestinal lamina propria until a relatively late stage
and correlate with the appearance of commensal organisms in
the cecum upon weaning. This was consistent with the fact
that the development of IL-17 cells depended on the presence
of a normal gut microflora and suggested that a particular
Figure 1. Effector and Regulatory Dendritic Cells
Antigen-sampling dendritic cells mediate induction of effector T cells.
CX3CR1
+ DCs (and/or DCs bearing other chemokine receptors) extend
processes (dendrites) between epithelial cells and into the gut lumen to sample
antigens associated with micro-organisms above the epithelial layer. These
cells then present antigen to CD4+ T cells that then become effector T cells
producing proinflammatory cytokines. Thus, antigen-sampling DCs serve
host-defense functions. DCs not involved in antigen sampling serve as
inducers of regulatory T cells. CD103+ DCs, probably after ‘‘conditioning’’ by
epithelial cells, present antigens to naive T cells in the context of retinoic
acid (RA) and TGF-b secretion. Antigens presented in this case access the
dendritic cell by antigen entry process not involving dendrite sampling.
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responsible for the development of IL-17 cells at this site. Exten-
sive studies of the composition of the gut microflora in mice from
different commercial sources that were and were not associated
with mouse colonies in which IL-17 was expressed and various
types of antibiotic treatment regimens narrowed the possible
IL-17-inducing bacteria to the bacterial phyllum known as the
Cytophaga-Flavobacter-Bacteroidetes (CFB) phyllum (Ivanov
et al., 2008). Further work will be required to more precisely
identify the member of this group that is the actual IL-17 inducer.
In addition, despite considerable study, the mechanism of IL-17
induction is unclear. One possibility that deserves consideration
is that the CFB organism induces epithelial cells to secrete
TGF-b or to produce factors that engender the development of
dendritic cells that secrete TGF-b because this cytokine is
uniquely involved in IL-17 production.
A second study also links the production of IL-17 in the intes-
tinal lamina propria to a member of the microflora, but in this
case, the link is with a specific organism rather than with a large
bacterial group containing many members (Wu et al., 2009). The
organism involved, Bacteroides fragilis, is found in both mouse
and human colons in either a nontoxigenic and toxigenic form,
the latter producing a metalloprotease toxin (B. fragilis toxin
[BFT]). The toxigenic form can cause acute colitis in humans
and is associated with the development of colon carcinoma in
long-term asymptomatic carriers. Of interest here, colon-
cancer-prone mice colonized with the toxin-producing form of
B. fragiliswere found to develop colits and to manifest increased
tumor development. This was associated with toxin-induced
STAT3 activation in epithelial cells and ‘‘immune’’ cells, which
usually indicates there is secretion of IL-6, a cytokine that has
been shown to support tumor growth (Becker et al., 2004;
Grivennikov et al., 2009). In addition, the T cells driving the
inflammation were mostly IL-17-producing T cells and the
lamina propria tissue containedmRNA encoding Th17 cell-asso-
ciated cytokines such as IL-23, IL-1b, and TGF-b. This was also
related to an IL-6-STAT3 response because it was not seen in
STAT3-deficient mice. Thus, in this case, the reason why coloni-
zation with toxin-producing B. fragilis is associated with IL-17
production in the lamina propria seems clear: the toxin induces
production of cytokines and signals that provide an ideal milieu
for the differentiation of Th17 cells. It should be noted, however,
that IL-17 induction in this case is occurring in the setting of
inflammation, rather than in the homeostatic environment that
prevails in small-intestinal IL-17 production induced by a CFB
organism.
Studies such as those described above identifying organisms
that induce an effector cytokine are complemented by a study
showing that a particular organism can induce the production
of a regulatory cytokine. Thus, intestinal colonization with a non-
toxin producing form of B. fragilis that produces polysaccharide
A (PSA) leads to the development of an anti-inflammatory state
mediated by PSA-induction of IL-10-producing regulatory cells
(Mazmanian et al., 2008). The mechanism of this effect was
shown in cell-transfer studies in which T cells obtained from
mice colonized with B. fragilis and transferred to Rag2/ recip-
ient mice protect the latter from Helicobacter hepaticus-induced
colitis, and such protection is abrogated by the administration of
anti-IL-10. The mechanism of induction of the IL-10-producingTreg cells has not yet been defined, and thus it is not known
whether the PSA is acting on epithelial cells to ‘‘condition’’ DC
responses so that they preferentially induce Treg cells or more
directly on DCs themselves. In both cells, PSA could be acting
through TLR2 because PSA has been shown to utilize TLR2 to
induce Th1 cell responses (Wang et al., 2006). These results
are of interest with respect to inflammatory bowel diseases
(IBDs) because it has been shown that at least some patients
with Crohn’s disease have reduced numbers of intestinal
bacteria because of loss of particular bacterial phyla from the
gut microflora (Frank et al., 2007); thus, it is possible that such
patients lack organisms such as B. fragilis that normally induce
regulatory cells.
The microflora may also act as a whole rather than individually
to affect mucosal cytokine responses. In some instances the
mechanism of such effects is undefined, whereas in others it
involves interactions between common bacterial components
and TLRs on epithelial cells or DCs. An excellent example of
this kind of ‘‘pan-microflora’’ mechanism is embedded in the
finding of Atarashi et al., who showed that a nonhydrolyzable
form of ATP administered to germ-free mice mediates the differ-
entiation Th17 cells but not Th1 cells (Atarashi et al., 2008). This
effect is mediated by CD70hiCD11clo DCs that can respond to
ATP in the absence of TLR stimulation. In addition, ATP stimula-
tion depended on the function of ATP receptors P2X and P2Y
and resulted in the production of IL-6 and TGF-b, the inducers
of Th17 cells. Finally, these authors showed with the transfer
model of colitis that Rag2/ mice that received naive CD4+
T cells and that were treated with ATP every 3 days during the
first 30 days after cell transfer develop more severe colitis than
untreated control mice. This latter finding correlates with the
fact that CD70+ DCs are drivers of both Th1 and Th17 effector
cell responses and depletion of these cells prevents experi-
mental colitis (Iwamoto et al., 2007; Manocha et al., 2009).
However, whether these cells are capable of forming antigen-
sampling dendrites is not known, and thus, it is not clear whether
the ATP acts specifically on dendrites that extend into the
mucosal lumen or more generally on DCs in the mucosal tissues
via diffusion into the latter sites. Finally, it seems unlikely that the
mechanism used by the CFB organism to induce IL-17 does not
involve secretion of ATP because such secretion is more likely
the property of many different bacteria rather than a single
species. However, this mechanism cannot be ruled out because
it is possible the CFB organism may more efficiently deliver ATP
to the mucosa by virtue of its juxtaposition to epithelial cells.
Another example of the microflora effect on DC responses
involves responses in which the microflora is acting through
epithelial cells to induce factors that subsequently affect DC
development. Whether this process involves many organisms
or particular organisms is not yet known, although the former is
more likely because epithelial cell responses are usually chan-
neled through receptors that are not organism specific.
The best-studied example of such epithelial cell-mediated
interaction involves the induction of TSLP (thymic stromal
lymphopoietin), an IL-7-like molecule that is produced by
epithelial cells in response to inflammatory cytokines such as
IL-1b and TNF-a or in response to TLR2 and TLR3 stimulation
(Liu et al., 2006; Wang and Liu, 2009) In studies exploring the
role of TSLP inmucosal DC responses, Rescigno and colleaguesImmunity 31, September 18, 2009 ª2009 Elsevier Inc. 379
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amass evidence supporting the view that epithelial cells stimu-
lated by commensal organisms secrete TSLP (and perhaps
TGF-b) and thereby promote resident CD11b+ DCs to secrete
IL-4 and IL-10 rather than IFN-g so as to maintain a Th2 cell-
dominant steady state in the uninfected lamina propria (Rimoldi
et al., 2005). This situation is dramatically changed by the pres-
ence of pathogens that have the capacity to induce epithelial
cells to produce various proinflammatory chemokines (e.g.,
CCL20), which then recruit ordinarily nonresident DCs from
Peyer’s patches; these cells then produce proinflammatory
cytokines such as IFN-g upon arrival in the lamina propria (Iliev
et al., 2007). In this scenario, the homeostatic DCs express
CX3CR1 and are involved in antigen sampling via dendrites; in
addition, they may also be involved in induction of regulatory
cells. In contrast, the DCs active in inducing Th1 cell-type
responses express CCR6; these cells are initially stationed close
to M cells in the Peyer’s patches and thus are subject to early
stimulation and maturation by entering pathogens.
This theory of epithelial orchestration of DC function in the
lamina propria is attractive but as yet unproven. One problem
is that the key role of TSLP has not yet been verified by studies
of mice with targeted deletion of this cytokine. In addition, this
theory predicts that lamina propria cells are mainly Th2 cell
oriented in the uninfected state, but in fact, Th1 cell cytokines
predominate at this site under these conditions. Finally, the
theory does not fully account for how epithelial cells distinguish
between commensal and pathogenic organisms and thus
switch from an anti-inflammatory to a proinflammatory posture.
Rescigno and colleagues suggest that commensal organisms
do not gain access to intracellular sites or basolateral sites of
epithelial cells and thus do not activate TLRs and NOD proteins
that would initiate proinflammatory programs. However, it is not
clear that proinflammatory TLR signaling is initiated exclusively
or at all from intracellular sites or that TLR signaling from surface
TLRs does not have proinflammatory consequences. In addition,
antigen sampling by dendrites, although controlled by TLR
signaling of epithelial cells, is not the exclusive province of
commensal organisms; it is also essential for optimal host
defense against pathogens (Niess et al., 2005).
More recently, Rescigno and colleagues have extended their
concept of epithelial orchestration of mucosal homeostasis
with studies suggesting that epithelial cells induce ‘‘tolerogenic
DCs’’ (Iliev et al., 2009a). In these studies, the authors showed
that mouse epithelial cells produce TGF-b and retinoic acid
(RA), which induce lamina propria to upregulate CD103. Such
epithelial cell-‘‘conditioned’’ CD103+ DCs then induce Foxp3+
Treg cells via production of TGF-b and RA with the capacity to
ameliorate colitis in an adoptive transfer system. In mouse
studies, epithelial TSLP production was not involved, but in
parallel studies of human epithelial cells, TSLP production along
with TGF-b and RA production participated in the induction of
the tolerogenic DCs, although the nature of this participation
was undefined. Tolerogenic DCs were found in mesenteric
lymph nodes and were therefore part of a migrating DC popula-
tion involved in responses to lumenal antigens. In addition,
epithelial cells obtained from patients with Crohn’s disease
lacked the ability to induce tolerogenic DCs, suggesting that
this abnormality is a cause of Crohn’s disease (Iliev et al., 2009b).380 Immunity 31, September 18, 2009 ª2009 Elsevier Inc.Other evidence that commensal organisms induce epithelial
cells to regulate responses in the mucosa comes from Jarry
et al., who focused on epithelia production of IL-10 and TGF-b
(Jarry et al., 2008). These investigators showed that epithelial
cells in human colonic mucosa explants produce IL-10 as well
as TGF-b and that blockade of these cytokines with anti-IL-10
and anti-TGF-b results in greatly increased IFN-g and TNF-a
production (presumably by lamina propria cells), which in turn
was associated with epithelial cell disruption, apoptosis, and
loss of barrier function. In addition, they showed that the TLR4
ligand LPS or bacteria induced IFN-g secretion when epithelial
production of IL-10 was blocked by anti-IL-10. The roles of
IL-10 and TGF-b in epithelial cell regulatory cytokine function
also comes from mouse studies in which it has been shown
that mice expressing an epithelial cell-specific IL-10-producing
transgene and mice in which mucosal TGF-b function is facili-
tated by downregulation of inhibitory Smad7 with Smad7 oligo-
nucleotide are resistant to experimental colitis (DeWinter et al.,
2002; Boirivant et al., 2006).
The ability of organisms in the microflora such as B. fragilis to
induce IL-17-producing cells or IL-10-producing cells as dis-
cussed above reflects a conventional inductive process wherein
the organism in the microflora is an agent of change in the status
of the mucosal immune system. It is possible, however, that the
mucosal immune systemmay exert control over the character of
the microbial flora and thereby reverse the inductive process.
This appears to be the case in a unique model of spontaneous
colonic inflammation consisting of Rag2/ mice that are also
deficient in T-bet, a factor better known for its ability to direct
Th1 cell differentiation (Garrett et al., 2007). As in other models
of spontaneous inflammation, the inflammation is prevented by
antibiotic treatment of the mice, indicating that the bacterial flora
was driving the colitis. More importantly, wild-type mice cross-
fostered by colitic mothers also developed colitis, albeit to
a less severe degree than the T-bet- and Rag2-deficient mice,
indicating that the bacterial flora in the colitic mice contained
colitogenic microflora that could vertically transmit colitis to
offspring. It thus appeared that the mucosal immune system in
T-bet- and Rag2-deficient mice had created conditions in the
gut lumen favoring the development of colitogenic microflora
capable of causing colitis in the absence of T-bet deficiency.
Although the mutant mice do not mimic any form of human
IBD, the fact that mice with any form of colitis can influence
the microflora so as to render them colitogenic for normal mice
has important implications. First, it implies that colitogenic
organisms do in fact exist and can be a cause of colitis and
second, it shows that colitis itself can create microbial niches
that support the development of colitogenic organisms.
Influences Exerted on Mucosal Dendritic Cells via TLR
Ligands
In the studies of the influences of the gut microflora on DCs, the
mechanism of interaction is rather poorly defined and only
assumed to be through an innate signaling receptor. There are,
however, several well-studied examples in which such influ-
ences have been related to a known receptor.
TLR2 signaling can affect mucosal responses at several levels
via effects on epithelial cells, DCs, Treg cells, and macrophages.
With respect to epithelial cells, TLR2 stimulation of epithelial cells
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epithelial barrier function by exerting antiapoptotic effects and
preserving tight junctions (Cario et al., 2007). This is manifest
in vivo by the fact that the administration of TLR2 ligand
(Pam3Cys-SK4) ameliorates DSS-induced colitis. These findings
thus support earlier studies showing that TLR2-deficient (and
TLR4-deficient)mice exhibit severeDSS-inducedcolitis because
ofmassive epithelial cell disruption (Rakoff-Nahoum et al., 2004).
There have been several reports that regulatory cells bear
TLR2 receptors and are directly inhibited by TLR2 ligands. For
example, TLR ligand inhibits proliferation of CD25+ Treg cells
and thus administration of ligand reduces Candida albicans
outgrowth (Sutmuller et al., 2006). Similarly, TLR2 ligand
signaling (in the presence of concommitant T cell receptor
signaling) inhibits Treg cell activity and prevents expression of
Foxp3, at least transiently (Liu et al., 2006). Whether these
TLR2 effects occur with respect to mucosal regulatory cells is
presently unknown. Other studies of the effects of TLR2 ligands
on Treg cell responses show that such effects can also involve
initial stimulation of DCs, which then induce suppressor T cells.
As mentioned above, this may be the mechanism by which
PSA derived from B. fragilis induced suppressor T cells (Mazma-
nian et al., 2008). Additional and more tangible evidence of TLR2
involvement in regulatory responses comes from mouse studies
showing that minimal disruption of the epithelial barrier caused
by administration of ethanol or AT1002 (V. cholera zona occlu-
dens toxin hexapeptide) leads to IL-10 secretion as well as the
induction of persistent CD4+ LAP+ (latent TGF-b-associated
with latency-associated peptide) cells (Boirivant et al., 2008)
(Figure 2). Of considerable interest is the fact that the latter cells
are atypical Foxp3 suppressor cells that renders the mouse
highly resistant to the induction of TNBS-colitis. The mechanism
of induction of these cells is not yet clear, but it is known that it
depends on the presence of an intact intestinal flora which
acts, at least in part, via TLR2 stimulation of lamina propria
CD11c+ DCs. Thus, it is possible that the induction of these cells
is a ‘‘front-line’’ regulatory mechanism that helps the gut main-
tain homeostasis in the face of minor or chance bacterial inva-
sion even before the mechanisms that induce Foxp3+ Treg cells
are called into play.
As a final word in discussing TLR2 effects on mucosal
responses, it is important to mention that such effects are likely
to be complex given the fact that TLR2 ligands signal via two
types of TLR2 receptors, one linked to TLR1 and one to TLR6.
That this has functional consequences is shown in a recent
study in which it was reported that TLR2 ligands that act through
TLR2 in combination with TLR6 tend to induce high amounts
of IL-10 and low amounts of IL-12, whereas TLR2 ligands that
act through TLR2 in combination with TLR1 have the opposite
consequences (Depaolo et al., 2008). Thus, the quality of the
TLR2 ligand can lead to very different responses.
Signaling ofmucosal DCs via TLR4 is arguably themost impor-
tant means of communication of gut microflora with mucosal
cells owing to the ubiquity of the TLR4 ligand LPS and the dual
MyD88 and Trif pathway of TLR4 signal transduction. It should
not be immediately assumed, however, that the dominant effect
of TLR4 signaling is proinflammatory for two reasons. First, TLR4
signaling (along with TLR2 signaling) of epithelial cells promotes
the epithelial integrity and restitution necessary to resist proin-flammatory influences (Rakoff-Nahoum et al., 2004). Second,
under conditions of chronic TLR4 stimulation in mucosal tissues,
TLR4 may induce a nonresponsiveness known as LPS or endo-
toxin tolerance that limits further responses, not only to LPS,
but to most other TLR ligands as well (Liew et al., 2005). Such
‘‘cross-tolerance’’ occurs via the induction of a variety of factors
that block both TLR4 and other TLR signaling pathways. The
most prominent of such factors is IRAK-M, amolecule expressed
by monocytes that interferes with IRAK-1 and IRAK-4 dissocia-
tion from MyD88 and the formation of IRAK-TRAF6 complexes
in the TLR signaling pathway (Kobayashi, et al., 2002). However,
Figure 2. Foxp3 Regulatory Cells Induced by Gut Microflora
Components
Administration of ethanol or V. cholera zona occludens toxin causes a transient
decrease in epithelial barrier function and increased exposure to gutmicroflora
components. This, in turn, leads to induction of Foxp3, LAP+ (latency-asso-
ciated protein-positive) regulatory T cells. CD11c+ DCs in the lamina propria
induce Foxp3, LAP+ regulatory T cells upon sensing a TLR2 ligand. Subse-
quent attempts to induce TNBS-colitis in these mice or in mice that are adop-
tively transferred with lamina propria cells from these mice are thwarted by the
presence of the regulatory T cells.Immunity 31, September 18, 2009 ª2009 Elsevier Inc. 381
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a deubiquitinating enzyme, and NF-kB p50, which when
produced in excess prevents productive NF-kB p50-p65 hetero-
dimer formation (Fan and Cook, 2004).
Studies by Elson and colleagues bear directly on the relevance
of TLR4 signaling or lack thereof to mucosal DC responses and
inflammation (Elson et al. 2005). These investigators showed that
a substrain of C3H/HeJ mice known as C3H/HeJBir mice with
defective TLR4 signaling caused by an inactivating mutation in
the Tlr4 gene are subject to spontaneous cecal colitis and that
this is associated with the presence of greatly increased
numbers of T cells exhibiting responses to antigens associated
with the bacterial flora (Sundberg et al., 1994; Cong et al.,
1998). They thus established that a defect in the innate immunity
could lead to inappropriate responses to components of the
normal gut flora and thus to mucosal inflammation. Given the
tendency of the TLR4 response to elicit general unresponsive-
ness to TLR stimulation discussed above, it might be assumed
that colitis in mice with TLR4 response defects is due to faulty
TLR4-induced tolerance, particularly in an immunologic micro-
environment that is replete with LPS. Evidence that this is the
case, however, is equivocal. Thus, in studies relevant to this
question, Beckwith et al. found that macrophages from C3H/
HeJBir mice as compared to C57BL/6 mice display increased
amounts of NF-kB p50, a possible inhibitor of TLR activation of
NF-kB as mentioned above. In addition, they found that stimula-
tion of macrophages from these mice with several TLR ligands
in vitro led to lower cytokine production (Beckwith et al., 2005).
However, in other studies, Beckwith et al. also showed that
T cells from C3H/HeJBir mice administered flagellin in vivo
mount increased cytokine responses after isolation and restimu-
lation in vitro with splenic antigen-presenting cells (APCs) pulsed
with flagellin (or other bacterial antigens) as compared to simi-
larly treated T cells from C57BL/6 mice (Beckwith et al., 2005).
This latter study evaluating the in vivo responses of C3H/HeJBir
DCs taken with the fact already mentioned that C3H/HeJBir
T cells exhibit increased responses to bacterial antigens would
suggest that C3H/HeJBir DCs, at least when stimulated in vivo,
are more capable of activating T cells than DCs from normal
mice. The picture that emerges then is that lack of TLR4 function
in C3H/HeJBir mice does in fact lead to increased stimulatory
function and that this increased function is what underlies the
tendency to mount increased responses to gut microflora and
to develop colitis. Therefore, the idea that a TLR4 defect leads
to disease because of reduced regulation seems to hold, but
clearly much more study is necessary to establish this point.
It is somewhat curious, given the profound nature of the
defect, that the colitis in C3H/HeJ mice was not particularly
robust in that it was a rather late developing manifestation and
was usually transient because of the appearance of suppressor
cells that quell the inflammation (Cong et al., 2002). In addition,
the fact that spontaneous colitis was limited to a substrain of
C3H/HeJ mice suggested that the LPS signaling defect is not
sufficient to cause colitis in and of itself. Indeed, in later studies
an additional colitis susceptibility locus in C3H/HeJBir mice was
identified on chromosome 3; such a locus is known as Cdcs1
and includes a gene encoding an NF-kB component, Nfkb1
(Beckwith et al., 2005). This locus may also affect TLR signaling
and NF-kB activation, so immunologic abnormalites in C3H/382 Immunity 31, September 18, 2009 ª2009 Elsevier Inc.HeJBir mice cannot be entirely attributed to a TLR4 defect.
This is borne out by the fact that congenic C3H/HeJBir mice in
which the chromosome 3 locus has been replaced by a
C57BL/6 locus exhibit less colitis. These clinical and genetic
features of C3H/HeJ colitis suggest that there is sufficient
redundancy in the innate immune system to overcome any one
defect and inflammatory disease inmice and in humans because
an innate immunity defect requires presence of additional risk
factors.
Studies of the responsiveness of the C3H/HeJBir mice show
that theymount increased T cell and B cell responses to antigens
associated with the microflora, but, whereas these stimulating
antigens may arise from a restricted subset of bacteria (particu-
larly with respect to B cell responses), there is little evidence that
a single type of bacteria or a single antigen is involved (Brand-
wein et al., 1997). Along these lines, serologic expression cloning
has disclosed that a surprisingly large percentage (as high as
25%) of the antigens eliciting responses in C3H/HeJBir mice
and in other mouse colitis models are flagellins, a fimbrial antigen
alluded to above that is associated with many bacteria (Lodes
et al., 2004). This, as well as the fact that flagellin-specific
T cells can mediate colitis in Rag2/ mice and that many
patients with Crohn’s disease (particularly those with stenosing
ileal disease) have antibodies to this antigen has led to the
concept that flagellin is an ‘‘immunodominant’’ antigen driving
the excessive mucosal responses associated with Crohn’s
disease (Targan et al., 2005; Shen et al., 2008). However, to
the extent that this implies that flagellin is the only antigen that
can induce inflammation in Crohn’s disease, thismay be an over-
interpretation of the data because it remains probable that
flagellin is but one of many antigens in the microflora capable
of eliciting inflammatory responses.
Flagellin, the ligand of TLR5, may act as an antigen in the
induction of Crohn’s disease. However, its function as a TLR5
ligand may play an important role in the induction of mucosal
DC responses and in this way also influence mucosal inflamma-
tion. Uematsu et al. have shown that a specific subset of lamina
propria DCs, CD11chiCD11bhi DCs, express TLR5 and induce B
cells to produce IgA in the absence of T cells upon stimulation
with flagellin (Uematsu et al., 2008). Spleen DCs stimulated
by LPS lacked this property. Interestingly, this property of
CD11chiCD11bhi DCs could be traced to their ability to produce
retinoic acid (RA). Furthermore, antigen-specific T cells stimu-
lated by antigen and flagellin-stimulated lamina propria
CD11chiCD1bhi DCs produced both IL-17 and IFN-g, whereas
flagellin-stimulated spleen DCs produced only IFN-g. This DC
effect on IL-17 production was also dependent on RA, and
indeed spleen DCs stimulated by LPS also induced IL-17 in the
presence of exogenous RA. It should be noted, however, that
in this case the RA effect was dose dependent and was positive
at low doses and negative at high doses.
Although TLR5 signaling of DCs was shown in the Uematsu
studies to mediate proinflammatory effects (i.e., IL-17 produc-
tion), in other studies it was shown that TLR5-deficient mice
are prone to develop colitis (Vijay-Kumar et al., 2007). Careful
analysis of this somewhat unexpected finding disclosed that in
the absence of epithelial cell TLR5 signaling, there is loss of
epithelial barrier function that leads, in turn, to increased adher-
ence of organisms to the epithelial surface and increased
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Effector Domain Ligand(s) Major Function Associated Diseases
NLRP1 (NALP1) Pyrin (PYD) Muramyl dipeptide (MDP) Procaspase activation/
IL-1b secretion
Vitiligo
NLRP3 (NALP3) Pyrin (PYD) ATP + TLR ligands Silica,
Aluminum
Procaspase activation/ IL-1b Muckle-Wells syndrome;
neonatal onset multisystem
inflammatory disease (NOMID)
NLRC4 (IPAF,
CARD12)
CARD/Pyrin Flagellin Procaspase activation/ cell death Pathogen clearance
NOD1 CARD g-D-glutamyl-meso-
diaminopimelic acid iE-DAP
Chemokine induction Mucosal pathogen clearance
NOD2 CARD Muramyl dipeptide NF-kB activation; TLR regulation Crohn’s disease; Blau syndrome
NOD-like receptor family members are intracellular proteins that initiate inflammatory reactions upon sensing a variety of ligands. Each member of
the family consists of a NOD (NACHT) oligomerization domain flanked by either a pyrin or card effector domain and a LRR (leucine-rich region) ligand
recognition domain.numbers of organisms in the spleen and liver. It was therefore
postulated that the inflammation was due to increased penetra-
tion of gut microflora into the underlying mucosa, which induces
inflammation mediated by other TLR ligands. Furthermore, it is
possible that in the absence of TLR5 there is less induction of
TLR-induced cross-tolerance of the type discussed above in
relation to TLR4 deficiency and thus enhanced and persistent
inflammation in response to the penetrating organisms.
The concept that a breach of the intestinal epithelial barrier by
organisms per se is a cause of inflammation is supported by
previous studies of mice that develop colitis because of faulty
epithelial cell adhesion and severely disrupted epithelial barrier
function caused by dominant-negative N-cadherin expression
(Hermiston and Gordon, 1995). In addition, it is supported by
the fact that mice with both TLR5 and TLR4 deficiency do not
develop coliits, presumably because these mice lack major
TLR mechanisms for sustaining inflammation in the first place
(Vijay-Kumar et al., 2007). It should be noted that the develop-
ment of colitis in mice with epithelial barrier dysfunction caused
by a TLR5 defect does not necessarily contradict the studies
described above in whichmice with epithelial barrier dysfunction
after ethanol administration developed increased resistance to
colitis caused by the induction of regulatory cells. These obser-
vations are reconciled if one assumes that the magnitude of the
bacterial invasion determines the type of mucosal response
elicited and that when only a small amount of organisms enter
the lamina propria, a regulatory response predominates. This
in turn implies that the difference between commensal organ-
isms’ and pathogens’ ability to induce inflammation is more
quantitative than qualitative.
TheRole of NOD2Signaling in the Regulation ofMucosal
Responses
The discussion above provides ample evidence that interactions
between components of the gut flora and TLRs have a profound
influence on mucosal responses, both positive and negative.
The story would not be complete however without a consider-
ation of the possible role of intracellular sensors of microbial
components by members of the NLR (nucleotide-binding
domain and leucine-rich repeat containing) family of proteins
whose members, structure, and function are summarized in
Table 1. Here, our attention will be directed mainly to NOD2,an NLR family member whose function has obvious significance
to mucosal homeostasis because polymorphisms in CARD15,
the gene encoding NOD2, have been shown to be major risk
factors in the development of Crohn’s disease, a disease that
is widely considered to arise from unregulated responses to
mucosal commensal organisms (Bouma and Strober, 2003;
Strober, 2007).
NOD2 is mainly present in APCs but it is also present in some
epithelial cells. Studies of NOD2 localization in epithelial cells
disclose that it is bound to either the cell membrane or vescular
membrane via its leucine-rich repeat (LRR) region and that such
binding is necessary for NOD2 activation of NF-kB (Barnich
et al., 2005). This localization pattern may facilitate interaction
withMDP released from extracellular or vesicular peptidoglycan.
Activation of NOD2 alone leads to a rather weak cytokine
responses, but NOD2 can considerable enhance costimulating
TLR responses (Kramer et al., 2006). Importantly, both the ability
of NOD2 to exhibit membrane localization and to activate NF-kB
is compromised by the presence of the Crohn’s disease-associ-
ated polymorphisms, at least in the case of the polymorphism
giving rise to a frameshift mutation and truncation of the LRR
(Girardin et al., 2003; Barnich et al., 2005; Kramer et al., 2006).
This correlates with the fact that CARD15 polymorphisms lead
to loss of the ability of NOD2 to induce cytokine responses
both in vitro and in vivo (Strober et al., 2006).
The impaired function of NOD2 resulting from Crohn’s-related
CARD15 polymorphisms created a theoretical dilemma because
it was difficult to explain how a loss of proinflammatory function
could increase risk for a disease characterized by increased
inflammatory responses. To overcome this problem, one had
to say that loss of NOD2 function leads to increase entry of
commensal organisms into themucosa followed by an increased
innate and adaptive response to such organisms bymechanisms
not requiring NOD2. A variation of this theory is that NOD2
dysfunction paves the way not to responses to commensal
organisms in general but rather to colitogenic organisms that
are particularly involved in the pathogenesis of Crohn’s disease,
such as the organism responsible for colitis in T-bet- and Rag2-
deficient mice or the IL-17-inducing organisms (Garrett et al.,
2007; Ivanov et al., 2008). This theory was supported by the
finding that NOD2 is not only present in APCs but also in distal
small intestinal epithelial cells, located at the base of themucosalImmunity 31, September 18, 2009 ª2009 Elsevier Inc. 383
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tion of small polypepide antibacterial agents called a-defensins
(Ogura et al., 2003; Salzman et al., 2007). Thus, it was possible
to say that NOD2 polymorphisms lead to decreased a-defensin
production and increased commensal bacteria in the intestinal
crypts and possibly in the lamina propria as well. This theory is
favored by the finding that NOD2deficiency inmice is associated
with decreased a-defensin production and increased suscepti-
bility to L. monocytogenes infection, an organism that initially
colonizes the gut (Kobayashi et al., 2005). In addition, it is favored
by the observation that the presence ofCARD15 polymorphisms
is associated with more severe a-defensin deficiency than is
normally seen in Crohn’s disease (Wehkamp et al., 2005). Finally,
it is favored by the fact that NOD2 polymorphisms tend to be
associated with Crohn’s disease affecting the terminal ileum,
the part of the GI track populated by a-defensin-producing
Paneth cells (Roesler et al., 2005).
Despite these supports, the idea thatCARD15 polymorphisms
lead to Crohn’s disease via a compromise in the ability of the
mucosal immune system to exclude one or more commensal
organisms from its internal milieu faces a number of objections.
Perhaps the most serious is the fact that the many studies of
the bacterial flora in Crohn’s disease have shown that although
the disease is associated with an increase in the number of
bacteria juxtaposed to the epithelial surface and changes in
the distribution of organisms comprising the microflora, there
is little evidence that the disease caused by a particular organism
or a group of organisms that penetrate the mucosa before the
onset of disease (Swidsinski et al., 2002; Kleessen et al., 2002;
Frank et al., 2007). This latter condition must be met if lack of
NOD2 function and consequent defective clearance of organ-
isms is a key Crohn’s disease-initiating factor. Studies of one
organism that has been proposed as a Crohn’s disease etiologic
agent and which comes closest to fulfilling this condition, enter-
oadherent/invasive (E-A/I) E. coli, is a case in point (Darfeuille-
Michaud et al., 2004). This agent is found in the inflamed ileal
mucosa of some 20%–30% of patients with Crohn’s disease
and in concentrations that correlates with severity of disease.
However, it is not present in the inflamed large bowel and there-
fore its role in disease causation is site specific and not appli-
cable to Crohn’s disease as a whole. E-A/I E. coli is a member
of the group of organisms that is increased in number in the
mucus layer overlying the apical surface of the epithelium of
patients with IBD but appears to be the only type of organism
with the capacity for epithelial invasion and penetration into the
mucosa proper in the absence of frank ulceration; however, fluo-
rescent in situ hybridization studies show that such penetration
is still limited to areas of erosion and ulceration (Kleessen
et al., 2002). The potential of E-A/I E. coli to cause inflammation
is also supported by in vitro studies showing that it has some of
the qualities of pathogenic E. coli in that it replicates within
macrophages and elicits macrophage proinflammatory cytokine
production (Bringer et al., 2006). These various characteristics of
E-A/I E. coli indicate that this organism can aggravate disease in
a pre-existing ileal Crohn’s lesion; however, its ability to initiate
disease is much less clear. This is highlighted by the aforemen-
tioned fact that actual penetration by the organism is associated
with area of erosion and by a recent finding that its initial
adherence to epithelial cells may be inflammation dependent.384 Immunity 31, September 18, 2009 ª2009 Elsevier Inc.In particular, it has been shown that adherence depends on an
interaction between bacterial type I pili and CEACAM6 on the
epithelial surface and that CEACAM6 expression is upregulated
by proinflammatory cytokines (Barnich and Darfeuille-Michaud,
2007). Thus, it seems likely that inflammation is a precondition
for invasion by E-I-A/I E. coli and that the organism does not in
fact initiate disease. As a generalization from the case of inva-
sive-E-I-A/I E. coli, it is unlikely that commensals initiate Crohn’s
disease by virtue of NOD2-mediated defects in bacterial clear-
ance if indeed the one organism with some of the properties
necessary for bacterial invasion and inflammation induction
does not do so.
A second problem with the idea that defective NOD2 function
causes Crohn’s disease by compromising the ability of the
mucosal immune system to exclude commensal bacteria from
the lamina propria relates to the aforementioned fact that
NOD2 mediates expression of a-defensin in Paneth cells in the
small intestinal crypts. First, the association of NOD2 polymor-
phisms and decreased a-defensin expression has been thrown
into doubt by a well-controlled study that relates a-defensin
expression to epithelial cell damage but not to NOD2 polymor-
phisms; this study, together with the initial observation that
correlated a-defensin expression with only one of the three
NOD2 polymorphisms, places a question mark on the signifi-
cance of a-defensin expression as either a primary abnormality
in IBD or an abnormality that explains NOD2 polymorphism
effects (Simms et al., 2008; Wehkamp et al., 2005). Second,
a-defensin deficiency in mice have been associated with
increased susceptibility to infection by pathogens (such as
Salmonella); this implies that patients should be more suscep-
tible to such infection as well (Ouellette, 2006). The fact is there
is no increase in enteric infection with common pathogens
in IBD, even though they are often treated with agents that
decrease host defense responses. This critique of the role of
a-defensin involvement in NOD2 polymorphisms also applies
to themore general idea discussed above implying that impaired
NOD2 function compromises responses to commensal organ-
isms after they enter the mucosa. Third, although it is often
assumed that increased numbers of bacteria in intestinal crypts
would predispose to intestinal inflammation, there is evidence
that the opposite is true. The latter consists of the observation
already discussed that agents that compromise the integrity of
epithelial cell tight junctions and thus lead to a ‘‘leakier’’ epithelial
barrier may in fact set in motion the stimulation of DCs that
induce Treg cells (Boirivant et al., 2008). Thus, although the
wholesale entry of commensal flora into the mucosa can indeed
cause inflammation, the entry of bacterial products (TLR ligands
and the like) could lead to responses that prevent inflammation.
Overall, then, although it seems premature to discount the effect
of NOD2 polymorphisms on defensins as a cause of NOD2-
related susceptibility, it is probably best to assume that this
effect is very unlikely to be the sole or even most important
explanation for this susceptibility.
If indeed the explanation of NOD2-related disease suscepti-
bility does not lie with its decreased function as an inducer of
host defense responses, what other explanation can be put
forward? An important possible answer to this question came
from the notion that because peptidoglycan (PGN) is the parent
molecule of MDP, it is possible that MDP signaling via NOD2
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byWatanabe et al. implied that this was the case by showing that
addition of MDP to cultures of PGN-stimulated DCs down-
modulated responses in cells from NOD2-intact mice but not in
cells from NOD2-deficient mice; moreover, PGN-induced
responses were intrinsically higher in NOD2-deficient mice,
implying a release from negative regulation (Watanabe et al.,
2004). Subsequent work expanding on this idea involved studies
of mice with heightened NOD2 responses, either by virtue of
NOD2 overexpression due to the presence of a NOD2 transgene
or by virtue of stimulation with increased amounts of MDP
(Yang et al., 2007; Watanabe et al., 2008). Mice bearing a
NOD2 transgene were found to have DCs that exhibited height-
ened downregulation of PGN responses during culture with
MDP. In addition, these mice were resistant to the induction of
TNBS-colitis, presumably because of downregulation of TLR
responses by MDP derived from the bacterial microflora. Simi-
larly, NOD2-intact mice administered MDP were highly resistant
to subsequent induction of TNBS-colitis, whereas NOD2-defi-
cient mice were not. In this case, the increased NOD2 signaling
could be shown to affect many TLR responses, not just the TLR2
response. Finally, in a combined experiment in which mice
bearing transgenic intact NOD2 or NOD2 with a Crohn’s disease
polymorphism led to a frameshift, administration of MDP was
found to protect mice from induction of TNBS-colitis in the
mice bearing the intact NOD2 but not in mice bearing the altered
NOD2 (Watanabe et al., 2008). This key study showed that the
Crohn’s disease polymorphism leads to altered negative regula-
tion by NOD2 and as such the polymorphism could lead to
increased TLR responses.
Themechanism of this regulatory NOD2 function was revealed
in studies of human cells wherein it was found that prestimulation
with MDP inhibited subsequent responses to TLR stimulation,
and such inhibition was prevented by gene silencing of a known
inhibitor of TLR signaling, IRF-4 (Watanabe et al., 2008). Subse-
quently, the inhibitory effect of IRF-4was supported by studies in
mice, in which it was shown that IRF-4-deficient mice were not
protected from colitis by MDP administration. However, other
studies in humans do not support the IRF-4 effect in that
although prestimulation with MDP inhibits subsequent TLR
responses, the inhibitory factor is IRAK-M (Hedl et al. 2007).
This discrepancy may be related to the types of APCs used in
the two studies. Another cogent finding in this latter study was
that TLR responses of cells from Crohn’s disease patients with
NOD2 polymorphisms were not inhibited by prestimulation
with MDP, indicating that the polymorphism in humans is, in
fact, attributable to a defect in MDP regulation. Just how IRF-4
(or IRAK-M) causes NOD2-mediated inhibition of TLR responses
is only now being explored. Preliminary studies indicate that
RICK binds to IRF-4, and such binding then inhibits RICK activa-
tion of TAK-1 and NF-kB. Although it is known that only NOD2
(and NOD1) induce activation of RICK, once the latter is acti-
vated it enhances TLR responses; conversely, RICK, in an inac-
tive state because it is bound to IRF-4, is able to interfere with
TLR responses (see Figure 3).
NOD2-deficient mice do not exhibit spontaneous colitis, indi-
cating that an abnormality of NOD2 is not by itself sufficient to
cause inflammatory disease. In studies exploring this insuffi-
ciency, it was shown that NOD2-deficient mice were susceptibleto an experimental colitis caused by intrarectal administration
of a recombinant E. coli expressing ovalbumin peptide to mice
with T cells bearing transgenic T cell receptors specific or oval-
bumin peptide (Watanabe et al., 2006). It was thus established
that in the absence of the regulating effect of NOD2, an adaptive
immune response, in this case to ovalbumin associated with the
E. coli, could cause colitis. This supports the idea that a NOD2
regulatory defect involving defect control of innate immune
responses collaborates with an adaptive immune response
to cause disease. It is thus likely that NOD2 susceptibility
Figure 3. Two Phases of NOD2 Function
Initial (proinflammatory) phase. NOD2 recognition of ligand (muramyl dipeptide
[MDP]) results in oligomerization and conformational changes that allow inter-
action between the CARD domain and RICK (RIP2). This is followed by ubiq-
uitination of RICK and activation of TAK1 and NF-kB. Ubiquitinated Rick
also leads to concomitant TLR signaling. Persistent (anti-inflammatory) phase.
NOD2 activation leads to induction of IRF4 synthesis and subsequent forma-
tion of RICK-IRF4 complex, which inhibits TLR signaling. Thus, administration
of MDP to mice inhibits experimental colitis.Immunity 31, September 18, 2009 ª2009 Elsevier Inc. 385
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to actually result in Crohn’s disease.
In summary, although NOD2 signaling may initially lead to
a positive response to MDP, in the mucosal immune system
that is replete with PGN and MDPs, a regulator defect ultimately
supervenes through the elaboration of IRF-4 or perhaps other
factors. The latter provides a tonic break on immune responses
in the mucosal immune system and helps maintain homeostasis
in the face of potential TLR hyperstimulation. Thus, the fact that
NOD2 dysfunction results in excessive mucosal responses
provides a molecular explanation of the prevailing concept that
IBD is due to hyperresponsiveness tomucosal antigens (Strober,
2008).
Conclusions
For themost part, the discussion above has concerned itself with
interactions between the gut microflora and mucosal DCs that
establish a homeostatic, noninflamed state. This arises from
the fact that, overall, these interactions strike a balance between
interactions leading to proinflammatory effects and those
leading to anti-inflammatory effects. It is important to under-
stand, however, that just as the proinflammatory interactions
can lead to amultiplicity of effector mechanisms, the anti-inflam-
matory interactions can also be complex and varied. Thus, Treg
cell responses don’t only involve Foxp3+ Treg cells; we have
seen that other types of regulatory cells are also operative.
Anti-inflammatory cytokine responses do not only involve IL-10
and TGF-b; there is evidence that it can also involve type 1 inter-
feron. Finally, and perhaps more importantly, it can involve
multiple and self-regulating mechanisms for limiting innate
immune responses including the notable example discussed
here, the NOD2-mediated inhibitory mechanism that, when
defective, can lead to Crohn’s disease.
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